Stay updated on HER2+ Breast Cancer Adjuvant Trial
Sign up to get notified when there's something new on the HER2+ Breast Cancer Adjuvant Trial page.

Latest updates to the HER2+ Breast Cancer Adjuvant Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant changes, including the removal of detailed descriptions of a clinical trial comparing treatments for HER2-positive breast cancer, while retaining some key identifiers such as the EudraCT number and the study's location.SummaryDifference41%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 11, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.SummaryDifference0.5%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check80 days agoChange DetectedThe study on HER2-positive early breast cancer has been updated to reflect a new patient allocation of approximately 520 instead of 700, and the hospital name has changed from Helsinki University Central Hospital to Helsinki University Hospital. Additionally, the last update date has been revised to February 2025.SummaryDifference2%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
Stay in the know with updates to HER2+ Breast Cancer Adjuvant Trial
Enter your email address, and we'll notify you when there's something new on the HER2+ Breast Cancer Adjuvant Trial page.